Abstract. In the early 1980s, the antischistosomal aryl hydantoin Ro 13-3978 (AH01), a close structural analogue of the androgen receptor antagonist nilutamide, was discovered. Administration of 100 mg/kg oral doses of AH01 to mice infected with adult and juvenile Schistosoma mansoni produced 95% and 64% total worm burden reductions, confirming its high activity against adult worms, and showing that AH01 is also effective against juvenile infections. AH01 had no measureable interaction with the androgen receptor in a ligand competition assay, but it did block dihydrotestosteroneinduced cell proliferation in an androgen-dependent human prostate cancer cell line. For AH01, nilutamide, and three closely related aryl hydantoin derivatives, there was no correlation between antischistosomal activity and androgen receptor interaction.
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Schistosomiasis is a neglected but widespread tropical disease caused by infection with parasitic blood flukes. Schistosoma mansoni, Schistosoma haematobium, and Schistosoma japonicum are the most widely distributed species and cause the highest disease burden, particularly in sub-Saharan Africa. [1] [2] [3] Praziquantel (PZ) is the only drug available for treatment of this disease, and it is active against adult schistosomes, but has little activity against the juvenile schistosomula, the young developmental stages of the parasite. 2, 4 Should serious praziquantel drug resistance arise, there are no viable alternatives to this drug. Even so, drug discovery for schistosomiasis has languished.
The introduction of PZ in 1982 likely led to decisions to abandon the development of a number of promising antischistosomal agents that were discovered in the same time period. One of these was Ro 13-3978 (AH01), the lead compound from a series of aryl hydantoins that were investigated in some detail at Hoffmann La-Roche. [5] [6] [7] [8] A number of these aryl hydantoins had high oral efficacy in schistosome animal models, 8 but they also produced antiandrogenic side effects in the host, 5 a not unexpected outcome given the close structural similarity of these aryl hydantoins to the antiandrogenic drug nilutamide (Figure 1 ). We recently showed 9 that nilutamide, but not the three structurally diverse androgen receptor (AR) antagonists flutamide, bicalutamide, and cyproterone acetate, has antischistosomal activity. As phylogenetic evidence indicates that schistosome species do not appear to have ARs, 10 the data led us to hypothesize that for aryl hydantoins and related heterocycles, the structural requirements for antischistosomal efficacy and AR binding interactions are divergent.
Based on the limited elucidation of the structureactivity-relationship of this aryl hydantoin compound series, 8 we began to test this hypothesis by the synthesis 8, 11 of AH01, its imino isostere AH02, and two derivatives (AH03 and AH04) incorporating nitrile functional groups (present in bicalutamide and other antiandrogens) known to import high AR binding affinity. 12 We now present our initial characterization of the antischistosomal versus antiandrogenic properties of these four aryl hydantoins.
Interaction of the aryl hydantoins with the AR was characterized by a ligand competition scintillation proximity assay 13 using a hexahistadine-tagged AR-ligand binding domain (LBD). Briefly, to each well of a 96-well Ni-chelate-coated Flashplate was added 80 μL of 5 μM AR-LBD in the assay buffer (25 mM HEPES, pH 7.2, 50 mM NaCl, 0.01% NP-40, 20 μM dihydrotestosterone [DHT], 2% dimethyl sulfoxide [DMSO]). After 60 min incubation, the protein solution was discarded followed by washes with assay buffer. Then, 40 μL of serially diluted aryl hydantoins in assay buffer containing 10% DMSO were added into each well followed by addition of 40 μL of 20 nM [
3 H]-DHT in assay buffer. The final assay solutions contained 5% DMSO. After sealing the plates and equilibrating for 18 h at 4 C, radio counts were measured and IC 50 values were calculated.
As expected, for the homologous DHT competition experiment, we measured a low IC 50 value of 76 nM, similar to the previously reported 13 value of 57 nM. Nilutamide and AH03 had IC 50 values of 7.4 and 1.5 μM, respectively, whereas the other aryl hydantoins had IC 50 values 27 μM. The binding competition observed for nilutamide and AH03 is consistent with previous data showing that AR ligands with aryl nitro or nitrile functional groups can form ion-dipole interactions with R752 in the AR ligand-binding domain. 12 To put the AR ligand competition data in context, we assessed the effects of the aryl hydantoins on androgendependent LNCaP C-33 human prostate cancer cells.
14 Briefly, LNCaP cells (passage nos. between 39 to 42) were plated at a density of 5 + 10 4 or 6 + 10 4 cells/well in 6-well plates for 72 h in a regular RPMI 1640 culture medium containing 5% fetal bovine serum (FBS), which was maintained at 37 C in a humidified atmosphere of 5% CO 2 . This was followed by continued cell culture for 48 h in a steroid-reduced medium consisting of phenol red-free RPMI 1640 containing 5% charcoal/dextrantreated FBS (v/v), 2 mM glutamine, and 50 μg/mL gentamicin. Cells were then exposed for an additional 72 h to 10 μM test compounds (from 10 mM DMSO stock solutions) with or without DHT (10 nM) after which time cell numbers were counted and cell growth relative to that of control cells was determined.
As expected, DHT significantly induced LNCaP cell proliferation, and this was blocked by the antiandrogen bicalutamide (P 0.0001) (Figure 2) . Similarly, AH01 and AH02 blocked DHT-induced LNCaP cell proliferation (P 0.001), but these *Address correspondence to Jonathan L. Vennerstrom, University of Nebraska Medical Center, College of Pharmacy, 986025 Nebraska Medical Center, Omaha, NE 68198-6025. E-mail: jvenners@unmc.edu compounds had no effect on basal cell growth. Conversely, nilutamide, AH03, and AH04 alone stimulated LNCaP cell growth (P 0.001), and for nilutamide, addition of DHT decreased (P 0.05) cell proliferation. These data indicate that nilutamide, AH03, and AH04 are AR agonists in this cell line. This is consistent with previous data 15 revealing that nilutamide acts as an AR agonist in LNCaP cells, presumably as a consequence of the T868A mutation in the ligand-binding domain of the AR expressed in this cell line. It is also possible that DHT may trigger a shutoff mechanism after maximal cell proliferation, consistent with previous results that LNCaP cells can respond to androgens in a biphasic concentrationdependent response. 16, 17 For these hydantoins, the apparent discrepancies between the ligand competition scintillation proximity assay and LNCaP cell proliferation data may also be the result of a differential antagonistic effect on tetrameric complex dissociation, AR dimerization, nuclear translocation, and AR interaction with androgen response elements in LNCaP cells. 18, 19 Thus, androgen-sensitive LNCaP C-33 cells may not be the ideal screen to assess the androgenic/antiandrogenic properties of aryl hydantoins.
In vivo (Table 1) antischistosomal activities against S. mansoni were assessed as previously described. 9 Briefly, mice were infected with~80 S. mansoni cercariae on Day 0 followed by administration of single 100 and 200 mg/kg oral doses of test compounds dissolved or suspended in a solubilizing 3% ethanol and 7% Tween 80 vehicle to groups of 4-5 mice on Day 21 post-infection (juvenile stage) and on Day 49 post-infection (adult stage). At 28 days post-treatment, animals were killed by the CO 2 method and dissected to assess total worm reductions.
Single 100 mg/kg oral doses of AH01 and AH02 administered to S. mansoni-infected mice on Day 49 post-infection (adult worms) afforded respective total worm burden reductions of 95% and 93%, confirming the previously reported 8 high activities (ED 50s of 38 and 37 mg/kg for AH01 and AH02) of these compounds. In this same schistosome mouse model, PZ has an ED 50 value of 172 mg/kg. 4 Similarly, administration of 100 and 200 mg/kg doses of AH01 and AH02 to S. mansoni-infected mice on Day 21 post-infection (juvenile worms) afforded respective total worm burden reductions of 64/88 and 51/88%; this clearly shows that aryl hydantoins, unlike PZ, have significant (P 0.05) activity against the juvenile stage of the parasite. In contrast to the high in vivo efficacies and lack of in vivo toxicity that we observed for AH01 and AH02, administration of single 200 mg/kg oral doses of AH03 and AH04 to S. mansoni-infected or uninfected mice led to the death of 60-100% of all animals within 4-5 days post-treatment. The observed toxicity of these two aryl hydantoins, the lack of apparent in vivo toxicity for nilutamide in this same experiment, 9 and the lack of interaction of AH04 with the AR, suggests that the in vivo toxicity of these aryl hydantoin derivatives derives in part from androgenindependent mechanisms.
In summary, we confirmed the high antischistosomal efficacy of AH01 and showed that this aryl hydantoin is also effective against juvenile infections. Furthermore, AH01 had no measurable interaction with the AR in a ligand competition assay, but it did block DHT-induced cell proliferation in androgen-dependent human prostate cancer LNCaP cells. For AH01, nilutamide, and the other aryl hydantoins, there was no correlation between antischistosomal activity and androgen receptor interaction.
Although previous investigations 6 show that AH01 produces schistosome worm lesions similar to those seen after PZ treatment, the molecular mechanism of action of this or related aryl hydantoins is unknown. However, based on our data, their antischistosomal properties do not seem to derive from interactions with the host AR. Finally, it is interesting to note that although schistosome species do not appear to have ANTISCHISTOSOMAL SELECTIVITY OF ARYL HYDANTOINS ARs, 10 Fantappié and others 20 discovered an expressed schistosome gene encoding the mitochondrial enzyme NADH ubiquinone oxidoreductase subunit 5 by screening a S. mansoni cDNA library with a human AR cDNA probe. This mitochondrial enzyme is thought to underlie the observed inhibition of S. mansoni growth by high concentrations of testosterone and dehydroepiandresterone. 20, 21 
